Takeda Pharmaceutical (TAK) Receivables - Other (2018 - 2025)
Takeda Pharmaceutical (TAK) has 8 years of Receivables - Other data on record, last reported at $380.5 million in Q1 2025.
- For Q1 2025, Receivables - Other rose 0.76% year-over-year to $380.5 million; the TTM value through Mar 2025 reached $380.5 million, up 0.76%, while the annual FY2025 figure was $381.1 million, 1.8% down from the prior year.
- Receivables - Other reached $380.5 million in Q1 2025 per TAK's latest filing, up from $377.6 million in the prior quarter.
- Across five years, Receivables - Other topped out at $714.3 million in Q1 2021 and bottomed at $377.6 million in Q1 2024.
- Average Receivables - Other over 5 years is $542.5 million, with a median of $559.4 million recorded in 2023.
- Peak YoY movement for Receivables - Other: plummeted 32.5% in 2024, then grew 0.76% in 2025.
- A 5-year view of Receivables - Other shows it stood at $714.3 million in 2021, then dropped by 4.68% to $680.9 million in 2022, then decreased by 17.84% to $559.4 million in 2023, then tumbled by 32.5% to $377.6 million in 2024, then increased by 0.76% to $380.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $380.5 million in Q1 2025, $377.6 million in Q1 2024, and $559.4 million in Q1 2023.